What changed: Alzheimer's disease

Indication page →

Every dated change on the records linked to Alzheimer's disease, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval6This record1

FollowWatch this record and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-22This recordAlzheimer's disease
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026ApprovalFlorquinitau F-18
Florquinitau F-18 approved in US
PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease, to identify patients with tau neurofibrillary tangle pathology

2020 · 1

2020ApprovalFlortaucipir F-18
Flortaucipir F-18 approved in US
PET imaging of the brain to estimate density and distribution of aggregated tau neurofibrillary tangles in adults with cognitive impairment being evaluated for Alzheimer's disease

2014 · 2

2004 · 1

2004ApprovalFludeoxyglucose F-18 (brain metabolism)
Fludeoxyglucose F-18 (brain metabolism) approved in US
FDG-PET nationally covered by Medicare specifically to differentiate Alzheimer's disease from frontotemporal dementia in patients with an uncertain diagnosis after comprehensive specialist evaluation (NCD 220.6.13)

2000 · 1

2000ApprovalIoflupane I-123
Ioflupane I-123 approved in EU
Detecting loss of functional dopaminergic neuron terminals in the striatum in clinically uncertain Parkinsonian syndromes, and to help differentiate probable dementia with Lewy bodies from Alzheimer's disease